AACR 2020: Liquid Biopsy Company Guardant Health Presents Colorectal Cancer Data, Outlines Plans For Regulatory Approval
Executive Summary
Guardant Health presented new clinical data at this week’s American Association for Cancer Research conference and outlined its growth plans as cancer testing volumes recover after the pandemic.
You may also be interested in...
Investors Pump $257M Into Thrive’s Liquid Biopsy Test
Thrive is developing CancerSEEK, a liquid biopsy test designed to detect cancers at earlier stages of disease.
Guardant Will Collaborate With Janssen On Lung Cancer Companion Diagnostic
The companies expect the Guardant360 CDx liquid-biopsy test to identify patients who will benefit from amivantamab, Janssen’s investigational drug for non-small cell lung cancer.
Grail Raises $390M In Series D Financing To Advance Blood Cancer Test
Liquid biopsy company Grail raised $390m in a fourth round of financing, bringing the total funding to $1.9bn.